BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

April 7, 2014 7:00 AM UTC

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was off $1.66 to $68.44 last week after FDA's Anti-Infective Drugs Advisory Committee voted unanimously in favor of approval of Sivextro tedizolid to treat acute bacterial skin and skin structure infections (ABSSSI). The PDUFA date is June 20.

FDA's Anti-Infective Drugs Advisory Committee also voted unanimously in favor of approval of Dalvance dalbavancin (RQ-00000002) from Durata Therapeutics Inc. (NASDAQ:DRTX) to treat ABSSSI. The PDUFA date is May 26...